

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

NCT06407232

Status	RECRUITING
Phase	Phase 3
Sponsor	University of Wisconsin, Madison
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (5)

- undergone kidney or simultaneous kidney/pancreas transplant
- high-risk CMV serostatus (D+/R-) at time of transplant
- develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)
- demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening
- able to provide informed consent to participate

Exclusion (5)

- contraindication to letermovir or its excipients
- develop ganciclovir-resistant CMV infection
- currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent
- unable or unwilling, in the opinion of the Investigator, to comply with the protocol
- pregnant or breastfeeding

Locations (1 total)

UW Hospital and Clinics, Madison, Wisconsin, United States